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Abstract
Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant
chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with
non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian
cancer.
Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage
non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were
evaluated according to histological subtypes.
Results: A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma,
31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of
low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after
the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease
≤1 cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for
performing NAC was high tumor burden (n= 106, 68.8%). The median progression-free survival (PFS) was 14.3months and
median overall survival (OS) was 52.9months. In multivariate analyses, mucinous and clear cell carcinoma were negative
prognostic factors for both PFS (p = 0.007 and p= 0.017, respectively) and OS (p= 0.002 and p= 0.013, respectively).
Conclusions: In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma
undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.
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Background
Ovarian cancer is the leading cause of death from gyneco-
logic malignancy worldwide [1]. In Korea, the incidence
and mortality rates of ovarian cancer are steadily increa-
sing [2–4]. The standard treatment for advanced-stage
ovarian cancer is cytoreductive surgery followed by
platinum-based combination chemotherapy [5, 6]. Despite
an initial response to standard treatment, the overall
5-year survival rate of advanced-stage ovarian cancer is
approximately 30% [7]. However, there has been no
significant change in the accepted approach to treatment
during the last two decades, which has hampered im-
provements in long-term survival [8].
In part, this is due to epithelial ovarian cancer being
considered as a heterogeneous disease across different
histologic subtypes, including high-grade serous carci-
noma (HGSC), clear cell carcinoma, endometrioid,
mucinous carcinoma, and low-grade serous carcinoma
(LGSC) [9]. Since 1999, the incidence of clear cell
carcinoma has increased markedly across all age groups
in Korea [10]. Furthermore, histologic subtypes other
than HGSC (non-HGSC) are known to have poorer clin-
ical outcomes in response to conventional chemotherapy
due to resistance and reduced sensitivity of these sub-
types to chemotherapy [11–15]. Previous clinical data
have indicated that survival outcome correlates with the
histological subtype [11]. However, all ovarian cancers
continue to be treated with the same therapeutic
strategy regardless of subtype.
Some previous studies showed that patients with
non-HGSC had poorer survival than those with HGSC
in primary debulking surgery (PDS) [14–18]. There are
several randomized studies showing that neoadjuvant
chemotherapy (NAC) is non-inferior to PDS for patients
with advanced epithelial ovarian cancer [19–21]. How-
ever, NAC has primarily been evaluated by studies focu-
sing on HGSC [22] and currently there are no published
studies on NAC outcomes in patients with non-HGSC.
Furthermore, although non-HGSC is considered a diffe-
rent disease entity than HGSC, it is not yet known
whether the selection criteria for NAC and the treat-
ment regimen of NAC should be the same for patients
with non-HGSC as those for patients with HGSC.
Therefore, we conducted a multicenter retrospective
cohort study to evaluate the clinical, surgical and sur-
vival outcomes of non-HGSC patients with advanced-
stage ovarian cancer after NAC.
Methods
From 2002 to 2017, 154 patients who had undergone NAC
for advanced stage non-HGSC were enrolled from 17 insti-
tutions affiliated with the Korean Gynecologic Oncology
Group (KGOG). We showed the number of enrolled
patients from each institution in Additional file 1: Table S1.
We performed a retrospective cohort study and data were
collected from medical records. This study was approved
by the institutional review boards of the participating cen-
ters in accordance with the Declaration of Helsinki and the
International Conference of Harmonization Good Clinical
Practice Guidelines.
Inclusion criteria for patients were as follows: (1) diag-
nosed and histologically confirmed with non-HGSC sub-
type of epithelial ovarian cancer; (2) diagnosed with
International Federation of Gynecology and Obstetrics
(FIGO) stage III or IV; (3) received at least 1 cycle of
NAC with or without interval debulking surgery (IDS);
and (4) had available medical records and follow-up
data. All cases diagnosed as non-HGSC subtype by cyto-
logic evaluation of ascites/pleural effusion, image-guided
aspiration biopsy, diagnostic laparoscopic/laparotomy
biopsy, or after IDS were included. The exclusion criteria
were as follows: (1) non-epithelial ovarian cancer; (2)
HGSC; (3) FIGO stage I or II; (4) borderline epithelial
ovarian cancer; and (5) PDS as primary therapy.
Reasons for the use of NAC varied due to the long-term,
multicenter, retrospective nature of this analysis. There-
fore, reasons for the use of NAC were collected from each
patient.
Clinical staging of epithelial ovarian cancer was per-
formed according to the FIGO system (2014) following
the use of computed tomography (CT) and positron emis-
sion tomography (PET)/CT for preoperative imaging
workup. Response to chemotherapy was evaluated after
the third cycle of NAC using the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria [23].
All patients received NAC as primary therapy with
various regimens in accordance with institutional policy.
Standard surgical procedure consisted of total hyster-
ectomy, bilateral salpingo-oophorectomy, omentectomy, or
retroperitoneal lymphadenectomy. Radical surgeries were
defined as bowel resection, diaphragm/peritoneal surface
stripping, splenectomy, liver resection, partial gastrectomy,
or partial cystectomy/ureteroneocystostomy. Postoperative
complications were graded according to the Memorial
Sloan-Kettering Cancer Center’s (MSKCC) surgical second-
ary events grading system [24]. We defined the major surgi-
cal complications as MSKCC grade ≥ 3. After surgery,
patients underwent various cycles and regimens of post-
operative adjuvant chemotherapy (POAC). Histologic
subtypes were confirmed according to the criteria of the
World Health Organization classification; however, there
was no central review of all microscopic slides. After the
completion of primary treatment, all patients underwent
institutional routine clinical follow-up, consisting of
imaging studies and blood tests. During follow-up, clinical
assessment including pelvic examination, serum CA-125
level were every 2–3months, and imaging studies such as
contrast-enhanced CT scan was performed every 6months.
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Statistical analysis
Continuous variables were described as median and
range (minimum and maximum value), while categorical
data were described by frequencies and percentages (%).
Progression-free survival (PFS) was defined as the time
from the date of first NAC to the date of first recurrence
or the date of last follow-up. Recurrence or progression
was diagnosed by radiologic finding, but not by elevated
CA-125 level alone. Overall survival (OS) was defined as
the time from the date of first NAC to the date of death
or the date of last follow-up. At each institution, sur-
vival data were extracted from their own cancer registry
linked with death certificate. Kaplan-Meier survival
curves were calculated using the log-rank test. Univa-
riate and multivariate analyses were evaluated using a
Cox proportional hazard model, and prognostic factors
affecting PFS and OS were evaluated. A p-value < 0.05
was considered to indicate statistical significance. Data
were analyzed with IBM SPSS, version 23 for Windows
(IBM Corp, Armonk, NY, USA).
Results
Baseline characteristics are shown in Table 1. Of the en-
rolled 154 patients, 20 patients (13.0%) were diagnosed
with mucinous adenocarcinoma; 31 (20.1%) with endo-
metrioid adenocarcinoma; 28 (18.2%) with clear cell
carcinoma; 29 (18.8%) with LGSC; and 12 (7.8%) with
carcinosarcoma. Three patients did not undergo IDS
and 8 patients did not receive POAC. The median num-
ber of NAC cycles, POAC cycles, and total chemother-
apy cycles were 3 (range: 1–10), 6 (range: 0–22), and 9
(range: 2–28), respectively. Most of patients treated with
a platinum-taxane combination of NAC (n = 152, 98.7%)
or POAC (n = 129, 83.6%). Various methods of diagnosis
were used before NAC: cytology of ascites in 59 cases
(38.3%), diagnostic laparoscopy/laparotomy in 41 cases
(26.6%), aspiration biopsy in 31 cases (20.1%), and
cytology of pleural effusion in 14 cases (9.1%). However,
histologic subtypes were confirmed before NAC in only
46 cases (n = 29.9%). Therefore, in some cases NAC was
administered regardless of histologic subtype and accor-
ding to criteria such as high tumor burden, older age, or
poor Eastern Cooperative Oncology Group (ECOG). The
reasons (multi-selectable) for NAC in patients with
non-HGSC were high tumor burden (n = 106, 68.8%), old
age/poor ECOG (n = 24, 15.6%), considered as HGSC
before NAC (n = 8, 5.2%), being referred from another
hospital after NAC (n = 5, 3.3%), and others such as policy
of each institution (n = 30, 19.5%). NAC was obtained in
13 patients (8.4%) with both high tumor burden and old
age/poor ECOG.
The median follow-up duration was 20.3 months
(range: 0.7–98.0 months), during which there were 107
recurrences and 56 deaths. Table 2 shows treatment
Table 1 Baseline characteristics of patients (n = 154)
Characteristics N (%)
Median age, years (range) 54.0 (27.0–79.0)
Median BMI at diagnosis, kg/m2 (range) 22.5 (12.9–31.9)
Median baseline CA-125 level, U/mL (range) 808.0 (9.0–19,800.0)
FIGO stage, n (%)
III 68 (44.2)
IV 86 (55.8)
ASA score, n (%)
1–2 122 (79.2)
3–4 21 (13.6)
Unknown 11 (7.2)
Histologic subtype, n (%)
Mucinous 20 (13.0)
Endometrioid 31 (20.1)
Clear cell 28 (18.2)
LGSC 30 (19.5)
Carcinosarcoma 12 (7.8)
Undifferentiated 20 (13.0)
Mixed 5 (3.3)
Anaplastic 2 (1.3)
Transitional 3 (2.0)
Squamous cell carcinoma 2 (1.3)
Ewing’s sarcoma 1 (0.6)
Method of diagnosis, n (%)
Ascites cytology 59 (38.3)
Pleural effusion cytology 14 (9.1)
Aspiration biopsy 31 (20.1)
Diagnostic laparoscopy 24 (15.6)
Diagnostic laparotomy 4 (2.6)
Laparoscopy in other hospital 12 (7.8)
Laparotomy in other hospital 1 (0.6)
Others 5 (3.3)
Not diagnosed before NAC 4 (2.6)
Confirm the histologic subtype before NAC, n (%)
No 108 (70.1)
Yes 46 (29.9)
HGSC 5 (3.3)
Mucinous 7 (4.6)
Endometrioid 4 (2.6)
Clear cell 8 (5.2)
LGSC 9 (5.9)
Carcinosarcoma 2 (1.3)
Others 11 (7.1)
Reasons for performing NAC*, n (%)
Old age / poor ECOG 24 (15.6)
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outcomes after NAC and surgical outcomes. In response
to NAC, decrease of CA-125 levels by more than 90% and
normalization of CA-125 levels (< 35U/mL) from baseline
to after the third cycle of NAC were observed in 61
(39.6%) and 49 (31.8) patients, respectively. After the third
cycle of NAC, 100 (64.9%) patients showed complete
remission or partial remission based on RECIST criteria.
However, we could not know the response rate after the
third cycle of NAC of 26 patients who received less than
3 cycles of NAC (n = 23) or did not perform any imaging
workup after the third cycle of NAC (n = 3).
Regarding surgical outcomes, 103 (66.9%) patients
underwent optimal debulking surgery (residual disease
≤1 cm). One hundred fifteen (74.7%) patients underwent
lymphadenectomy and of these, 63 patients (40.9%) had
lymph node metastasis. Sixty-three (40.9%) women
had positive peritoneal cytology during IDS. Eight
patients (5.2%) experienced major complications (MSKCC
grade ≥ 3) related to surgery.
Survival analysis showed that the median PFS was
14.3 months and the median OS was 52.9 months (Fig. 1).
The Kaplan-Meier curves stratified by histologic sub-
types are shown in Fig. 2. PFS and OS differed signifi-
cantly according to histologic subtypes (PFS, p = 0.002;
OS, p < 0.001). The median PFS by subtype was as
follows: 6.9 months for mucinous adenocarcinoma,
17.4months for endometrioid adenocarcinoma, 9.6
months for clear cell carcinoma, 16.6months for LGSC,
and 12.6 months for carcinosarcoma. The median OS
by subtype was as follows: 12.2 months for mucinous
adenocarcinoma, 35.7 months for clear cell carcinoma,
Table 1 Baseline characteristics of patients (n = 154) (Continued)
Characteristics N (%)
High tumor burden 106 (68.8)
Considered as HGSC before NAC 8 (5.2)
Refer from other hospital after NAC 5 (3.3)
Others 30 (19.5)
NAC regimens, n (%)
Paclitaxel + carboplatin 137 (89.0)
Paclitaxel + cisplatin 6 (3.9)
Docetaxel + carboplatin 8 (5.2)
Paclitaxel + carboplatin + bevacizumab 1 (0.6)
Others 2 (1.3)
POAC regimens, n (%)
Paclitaxel + carboplatin 114 (74.0)
Paclitaxel + cisplatin 5 (3.2)
Docetaxel + carboplatin 9 (5.8)
Paclitaxel + carboplatin + bevacizumab 1 (0.6)
Others 17 (11.0)
Not done 8 (5.2)
BMI body mass index, CA 125 cancer antigen 125, FIGO Federation of
Gynecology and Obstetrics, ASA American Society of Anesthesiologists, NAC
neoadjuvant chemotherapy, POAC postoperative adjuvant chemotherapy,
HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma, ECOG
Eastern Cooperative Oncology Group
*Multi-selectable
Table 2 Treatment outcomes after NAC/IDS
Characteristics N (%)
NAC response
CA-125, n (%)
CA-125 after 3rd NAC < 35 49 (31.8)
CA-125 reduction rate≥ 90% 61 (39.6)
Response rate after 3rd NAC, n (%)
CR 2 (1.3)
PR 98 (63.6)
SD 21 (13.6)
PD 7 (4.5)
Unknown 26 (16.9)
Surgical outcome
Surgery extent, n (%)
Standard 82 (53.3)
Radical 69 (44.8)
Not surgery 3 (1.9)
Residual disease after IDS, n (%)
≤1 cm 103 (66.9)
>1 cm 25 (16.2)
Unknown 26 (16.9)
Lymphadenectomy, n (%)
(−) 36 (23.4)
(+) 115 (74.7)
Unknown 3 (1.9)
Lymph node metastasis, n (%)
No 88 (57.2)
Yes 63 (40.9)
Unknown 3 (1.9)
Peritoneal cytology, n (%)
Negative 57 (37.0)
Positive 63 (40.9)
Not tested 27 (17.5)
Unknown 7 (4.6)
Postoperative complications*
0–2 143 (92.9)
3–5 8 (5.2)
Unknown 3 (1.9)
NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HGSC high-
grade serous carcinoma, CA 125 cancer antigen 125, CR complete response, PR
partial response, SD stable disease, PD progressive disease
*According to the Memorial Sloan-Kettering Cancer Center’s surgical secondary
events grading system
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65.9 months for LGSC, and 31.0 months for carci-
nosarcoma, while the median OS for endometrioid
adenocarcinoma was not reached. Overall, mucinous
adenocarcinoma and clear cell carcinoma appeared to
have the poorest survival prognosis. Multivariate Cox
proportional hazards regression showed that American
Society of Anesthesiologists score, residual tumor, and
lymph node dissection all demonstrated an independent
significant impact on PFS and OS. Furthermore, mucinous
carcinoma was found to be a significantly negative pre-
dictor for both PFS (hazard ratio [HR]: 2.31, 95% confi-
dence interval [CI]: 1.26–4.24, p = 0.007) and OS (HR:
3.24, 95% CI: 1.54–6.82, p = 0.002). Similarly, clear cell
carcinoma also appeared to be a poor prognostic factor
for both PFS (HR: 1.92, 95% CI: 1.12–3.29, p = 0.017) and
OS (HR: 2.56, 95% CI: 1.21–5.30, p = 0.013) in patients
who received NAC (Table 3). Survival outcomes were
significantly poorer in patients with mucinous (PFS,
p < 0.001; OS, p < 0.001) or clear cell subtype (PFS, p= 0.001;
OS, p = 0.002) compared to other subtypes (Fig. 3).
Discussion
In this multicenter retrospective cohort study, we found
that non-HGSC had a poor response rate after the third
cycle of NAC, low rate of optimal debulking surgery
compared to other studies mainly focused on HGSC. In
the CHORUS trial [19], HGSC subtype rate was 71%
and optimal debulking surgery rate was 73% and in
Surgical Complications Related to Primary or Interval
Debulking in Ovarian Neoplasms [21], HGSC subtype
rate was 98.1%, optimal debulking surgery rate was
90.4%, and complete response/partial response rate
according to RECIST was 90.9% in the NAC group.
(a) (b)
Fig. 1 Kaplan-Meier survival curves for patients with non-HGSC. Progression-free survival (a). Overall survival (b). HGSC, high-grade
serous carcinoma
(a) (b)
Fig. 2 Kaplan-Meier survival curves stratified by histologic subtype. Progression-free survival (a). Overall survival (b)
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The survival outcome in our study was not poor com-
pared to the European Organization for Research and
Treatment of Cancer (EORTC) 55,971 [20] and in the
CHORUS trial. The median PFS and OS for patients
were 12 and 30months, respectively, in the EORTC
study and 12 and 24.1 months, respectively, in the
CHORUS trial in the NAC group. However, we found
that mucinous and clear cell subtypes in our study have
poor survival from survival curves stratified by histologic
subtypes and they could be independent prognostic
factors for survival.
Ovarian cancer is typically considered as a single disease
with a notably heterogeneous group of neoplasms. In par-
ticular, the pathogenesis of non-HGSCs has been shown
to be unique for each histologic subtype, and the clinical
understanding of the pathology and molecular biology of
each subtype continues to improve. However, the current
guidelines suggest the same treatment strategies for
patients with ovarian cancer regardless of subtype. The
findings of the present study show that different histologic
subtypes have different prognoses, and the response to
standard chemotherapy is generally poor in non-HGSC.
Therefore, further studies and approaches that explore
individualized treatment strategies for histologic subtypes
are necessary.
In the NAC setting, maximal surgical effect is excluded
and sensitivity and response to NAC has been a well-
known prognostic factor for survival in advanced-stage
Table 3 Univariate and multivariate analyses for progression-free and overall survival using the Cox proportional hazard model
Variables PFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (years)
<55 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
≥55 0.99 (0.67–1.44) 0.939 1.33 (0.80–2.20) 0.268 1.14 (0.67–1.92) 0.634 1.51 (0.75–3.04) 0.245
ASA
1–2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
3–4 2.29 (1.37–3.84) 0.002 2.38 (1.26–4.51) 0.008 3.12 (1.64–5.90) < 0.001 3.24 (1.54–6.82) 0.009
Baseline CA-125 level (U/ml)
≤800 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
>800 1.04 (0.71–1.53) 0.826 1.14 (0.69–1.90) 0.605 0.79 (0.47–1.34) 0.382 0.93 (0.45–1.91) 0.838
FIGO stage
III 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
IV 0.91 (0.62–1.33) 0.629 0.74 (0.47–1.18) 0.210 0.75 (0.44–1.26) 0.277 0.62 (0.32–1.24) 0.177
Histology
Others 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Mucinous 2.64 (1.54–4.50) < 0.001 2.31 (1.26–4.24) 0.007 4.69 (2.48–8.85) < 0.001 3.24 (1.54–6.82) 0.002
Clear cell 2.10 (1.30–3.42) 0.003 1.92 (1.12–3.29) 0.017 2.62 (1.37–4.99) 0.004 2.56 (1.21–5.30) 0.013
Residual disease
≤1 cm 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
>1 cm 2.86 (1.75–4.66) < 0.001 2.40 (1.43–4.04) 0.001 3.46 (1.89–6.33) < 0.001 2.43 (1.28–4.63) 0.007
Surgery extent
Standard 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Radical 0.94 (0.64–1.39) 0.771 1.75 (1.02–2.99) 0.042 0.98 (0.57–1.67) 0.933 1.86 (0.97–3.56) 0.062
LND
No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Yes 0.67 (0.17–2.76) 0.004 0.33 (0.18–0.61) < 0.001 0.36 (0.09–1.49) 0.002 0.32 (0.16–0.62) 0.001
LN metastasis
No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Yes 1.03 (0.25–4.26) 0.074 2.89 (1.65–5.07) < 0.001 0.46 (0.11–1.97) 0.553 1.78 (0.74–4.32) 0.201
PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists, CA-125 cancer antigen 125,
FIGO Federation of Gynecology and Obstetrics, M/C Mucinous/Clear, LND lymph node dissection, LN lymph node
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ovarian cancer. While patients with HGSC tend to have
good responses to taxane-platinum combination regimens,
there are limited comparable data for patients with
non-HGSC. Non-HGSC is not as frequent as HGSC, and
thus it can be difficult to acquire prospective data. With
data of the Korean Central Cancer registry, we previously
showed that no improvement of survival outcomes was ob-
served for patients with clear cell carcinoma and mucinous
carcinoma during the past 20 years [8]; additionally, it was
not clear whether the selection criteria and regimen of
NAC for patients with non-HGSC should be the same as
those of patients with HGSC.
In the current study, confirmation of the histologic
subtype before NAC was not common; indeed, the histo-
logic subtypes of only 46 patients (29.9%) were identified
before NAC. Thus, approximately 70% of the patients in
our cohort received NAC without a histologic subtype
evaluation. Histologic subtypes can be determined by
diagnostic laparoscopy/laparotomy relatively easily, but
cytologic evaluation of ascites and pleural effusions is
more difficult. In our cohort, diagnostic laparoscopy/
laparotomy was performed for just 41 patients (26.6%).
An increased use of diagnostic laparoscopy could im-
prove the rate of patients for whom histologic subtypes
are identified prior to the decision to use treatment
options such as PDS or NAC. Although we could not
be sure for improved survival if patients without deter-
mining histologic subtypes underwent PDS instead of
NAC, we could at least give a chance for clinical trials
targeting specific molecular alterations associated with
histologic subtypes. There is an unmet clinical need for
novel therapeutic approaches tailored to patients with
non-HGSC after NAC.
Recently, studies of specific histologic subtypes have been
completed or are ongoing. For example, significantly higher
levels of estrogen receptor (ER), progesterone receptor
(PR), and E-cadherin have been shown to be expressed in
LGSC compared to HGSC, [25] and a consideration of
these differences may lead to the development of different
therapeutic strategies [26–29]. Based on retrospective
studies [29] showing the benefits of letrozole maintenance,
MD Anderson group suggested a randomized phase III trial
comparing letrozole and chemotherapy in LGSC. The MEK
inhibitor (MILO) trial is a phase III study investigating the
efficacy of MEK 162, a MEK inhibitor, compared to phy-
sician choice chemotherapy for recurrent or persistent
LGSC. A phase III trial (Gynecologic Oncology Group
(GOG)-241) compared the efficacy of chemotherapy regi-
mens for mucinous carcinoma: capecitabine-oxaliplatin ver-
sus carboplatin-paclitaxel and with or without bevacizumab
in mucinous subtype tumors was closed early for slow
accrual, and neither of regimen clearly improved PFS or OS
[30, 31]. Furthermore, in mucinous carcinoma, trastuzu-
mab (Herceptin) may be effective for patients with HER2
overexpression [32].
Efforts are ongoing worldwide to identify better stra-
tegies for treating clear cell carcinoma, as conventional
chemotherapy is considered to be less effective for this
particular subtype. One randomized phase III trial
(Japanese Gynecologic Oncology Group (JGOG) 3017)
compared an irinotecan-cisplatin regimen with a conven-
tional paclitaxel-carboplatin regimen for clear cell carci-
noma, but the irinotecan-cisplatin regimen did not show a
significant survival benefit [33]. Clear cell carcinoma
frequently has both PIK3CA mutation (oncogene) and
ARID1A mutation (tumor suppressor gene) [34]. The
GOG recently completed accrual of patients for a front-
line, phase II study of temsirolimus, an mTOR inhibitor,
used following paclitaxel/carboplatin as a first-line therapy
in treating patients with newly diagnosed stage III/IV clear
(a) (b)
Fig. 3 Kaplan-Meier survival curves for patients with mucinous or clear cell carcinoma compared to other subtypes. Progression-free survival (a).
Overall survival (b)
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cell carcinoma (GOG-268). However, studies of each
non-HGSC subtypes have been evaluated only in patients
who underwent PDS. There are no studies to identify
better strategies or develop of novel molecular target
therapy for non-HGSC subtypes in patients who under-
went NAC/IDS. Therefore, further studies are needed to
suggested optimal therapies for non-HGSC subtypes.
This study has several limitations. First, a central path-
ology review was not performed. Central pathology
review could establish uniform pathologic criteria for
specimens from patients used in studies by reducing
interobserver variability. Furthermore, this study in-
cludes quite a number of undifferentiated subtypes with
unclear specific subtype. These data could be more
accurately represented by a central pathology review.
Second, because this study was performed as a multicen-
ter retrospective analysis, no uniform selection criteria
for NAC were established. Selection for NAC was deter-
mined by the patient’s physical status, age, extent of the
tumor burden, and policy of each institution, among
other factors.
Despite these limitations, however, the current study is
an important contribution to existing literature, as it is the
first large retrospective analysis to evaluate the outcomes
of non-HGSC patients after NAC in advanced-stage
ovarian cancer.
Conclusions
In this study, significantly poor response rates and low
rate of optimal debulking surgery were observed among
patients with non-HGSC subtypes. Mucinous and clear
cell carcinomas in particular could be negative prognostic
factors for survival. Therefore, our findings suggest that
different treatment strategies are essential and further
studies with addition of targeted agents based on bio-
marker should be incorporated with priority to improve
survival outcomes of patients with this disease subset.
Additional file
Additional file 1: Table S1. The list of enrolled patients from each
institution (DOCX 24 kb)
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